Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Realbio Completes $15 Million Series A+ for Genome and Microbiome Screening

publication date: Apr 18, 2019

Realbio Technology (RBT), a Shanghai genomic screening company, raised $15 million in a Series A+ funding. The company has a dual focus on colorectal and microbiome screening. RBT operates in three areas: REALGENE provides scientific research services; REALMED offers early detection of disease based on genomic sequencing including microbiome research, and REALAGR specializes in animal genomics. Founded in 2014, RBT has set up branches in Hangzhou, Qindao, Guiyang and other places. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital